HBED
Based on 1 Customer Validation
HBED is an iron-chelating antioxidant. HBED chelates ferrous iron, promotes its oxidation to ferric iron, and blocks superoxide-driven ferric iron reduction, preventing Haber-Weiss/Fenton hydroxyl radical production. HBED donates H/electrons, undergoes protonation, reduces radical cations, and forms phenoxyl radicals. HBED exerts cytoprotective effects against peroxide-induced lung fibroblast injury. HBED crosses the blood-brain barrier and mitochondrial membrane, exhibits iron affinity/selectivity, and induces iron clearance in iron-loaded monkeys. HBED reduces hippocampal AQP4, microgliosis, oxidative stress, cerebral edema, and hippocampal swelling, and improves motor function/recovery after traumatic brain injury. HBED can be used in research on iron overload and traumatic brain injury (TBI).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.16%
- CAS No.: 35998-29-9
- Formule: C20H24N2O6
- Masse moléculaire:388.41
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-100579
Ferrostatin-1Ferroptosis Inhibitor -
HY-15763
ErastinFerroptosis Inducer -
HY-106376
DL-Buthionine-(S,R)-sulfoximineGlutamylcysteine Synthetase Inhibitor -
HY-12726
Liproxstatin-1Ferroptosis Inhibitor -
HY-B1645
Ammonium iron(III) citrateFerroptosis Activator -
HY-106376A
L-Buthionine-(S,R)-sulfoximineG-glutamylcysteine Synthetase Inhibitor -
HY-136057
iFSP1FSP1 Inhibitor -
HY-114481
Imidazole ketone erastinFerroptosis Inducer -
HY-103087
FIN56Ferroptosis Inducer -
HY-129457
FINO2Ferroptosis Inducer -
HY-139087
Erastin2xc(-) Cystine/Glutamate Transporter System Inhibitor, ferroptosis inducer -
HY-115319
CP-24879 hydrochloridedelta5D/delta6D Inhibitor
Activité biologique
Description
IC50 & Target
[2]|
AQP4 |
In Vitro
HBED undergoes HRP/H2O2-dependent one-electron oxidation to generate a phenoxy radical intermediate[1].
HBED promotes Fe (II) autoxidation, with maximum O2 consumption at an [HBED]/[Fe (II)] ratio of approximately 1[1].
HBED (≥100 μM; H2O2 750 μM; exposure 1 h; pre-incubation 2 h) protects Chinese hamster V79 lung fibroblasts against H2O2- and t-BuOOH-induced cytotoxicity, providing complete protection against H2O2 at ≥100 μM without pre-incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 4.5 months old)[2]
-
Dosage:100 mg/kg loading; 50 mg/kg every 12 h for 72 h; total first 24 h: 150 mg/kg; subsequent 24 h: 100 mg/kg/24 h
-
Administration:subcutaneous; immediately after TBI onset then every 12 h; 72 h
-
Result:Improved behavioral outcomes.
Reduced the volume of cortical injury, the cerebral hemisphere, and hippocampal swelling by 36.6%, 13.3%, and 23.4%, respectively.
Decreased the expression levels of hippocampal aquaporin-4 (AQP4), corpus callosum ionized calcium-binding adapter molecule 1 (Iba1), hemispheric Iba1, and corpus callosum 4-hydroxynonenal (4-HNE) by 81.8%, 39.8%, 42.4%, and 80.5%, respectively.
Chemical Information
-
CAS No. 35998-29-9
-
Appearance Solid
-
Masse moléculaire 388.41
-
Formule C20H24N2O6
-
Color White to off-white
-
SMILES
OC1=CC=CC=C1CN(CC(O)=O)CCN(CC2=CC=CC=C2O)CC(O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 5.56 mg/mL (14.31 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.56 mg/mL (1.44 mM); Clear solution
This protocol yields a clear solution of ≥ 0.56 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.6 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.56 mg/mL (1.44 mM); Clear solution
This protocol yields a clear solution of ≥ 0.56 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.6 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (288 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5746 mL | 12.8730 mL | 25.7460 mL | 64.3650 mL |
| 5 mM | 0.5149 mL | 2.5746 mL | 5.1492 mL | 12.8730 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5746 mL | 6.4365 mL |
HBED Related Classifications
HY-114837 Related Classifications
Powered by Bioz